Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Charlotte Suppli Ulrik

doi:10.2174/1874306401206010150

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Charlotte Suppli Ulrik

Research output: Contribution to journal › Journal article › Research › peer-review

10 Citations (Scopus)

Abstract

Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.

Original language	English
Journal	The Open Respiratory Medicine Journal
Volume	6
Pages (from-to)	150-4
Number of pages	5
ISSN	1874-3064
DOIs	https://doi.org/10.2174/1874306401206010150
Publication status	Published - 2012

Access to Document

10.2174/1874306401206010150

Cite this

@article{3603ff7253aa4a778a706ffc7a4e8898,

title = "Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD",

abstract = "Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.",

author = "Ulrik, {Charlotte Suppli}",

year = "2012",

doi = "10.2174/1874306401206010150",

language = "English",

volume = "6",

pages = "150--4",

journal = "The Open Respiratory Medicine Journal",

issn = "1874-3064",

publisher = "Bentham Open",

}

TY - JOUR

T1 - Aclidinium Bromide

T2 - Clinical Benefit in Patients with Moderate to Severe COPD

AU - Ulrik, Charlotte Suppli

PY - 2012

Y1 - 2012

N2 - Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.

AB - Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.

U2 - 10.2174/1874306401206010150

DO - 10.2174/1874306401206010150

M3 - Journal article

C2 - 23264836

SN - 1874-3064

VL - 6

SP - 150

EP - 154

JO - The Open Respiratory Medicine Journal

JF - The Open Respiratory Medicine Journal

ER -